Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a biopharmaceutical company focused on developing potential best-in-class medicines for patients suffering from serious and rare diseases. The company's pipeline includes two lead programs targeting thyroid eye disease (TED) and a portfolio of neonatal Fc receptor (FcRn) inhibitors for autoimmune disorders.
Viridian's financial performance in 2023 reflects its ongoing investment in research and development to advance its promising pipeline. For the full year 2023, the company reported annual revenue of $314,000 and a net loss of $237,734,000. Operating cash flow for the year was negative $184,170,000, while free cash flow was negative $185,068,000. These financial results underscore Viridian's focus on clinical development rather than near-term commercialization.
In the first quarter of 2024, Viridian continued to make significant progress across its portfolio. The company reported quarterly revenue of $72,000 and a net loss of $48,542,000. Operating cash flow for the quarter was negative $45,223,000, while free cash flow was negative $45,223,000. These quarterly results reflect Viridian's ongoing investment in its clinical programs.
Business Overview
Viridian's strategy is to identify market opportunities where there is a clear unmet need and the potential to develop differentiated products. The company then aims to engineer the best possible therapeutics and rapidly advance its programs to patients.Thyroid Eye Disease (TED) Portfolio
Viridian's lead programs are focused on the treatment of TED, a serious and debilitating autoimmune condition characterized by inflammation and damage to the tissues around and behind the eyes. The company is developing two anti-IGF-1R antibodies for TED: VRDN-001, an intravenously (IV) delivered monoclonal antibody, and VRDN-003, a subcutaneously (SC) administered antibody.VRDN-001 Program
VRDN-001 is Viridian's lead product candidate for the treatment of TED. In Phase 2 clinical trials, VRDN-001 demonstrated robust clinical activity and a favorable safety profile in both active and chronic TED patients after just two infusions. Viridian is currently conducting two global Phase 3 trials, THRIVE and THRIVE-2, to evaluate the efficacy and safety of VRDN-001 in patients with active and chronic TED, respectively. The company recently announced that THRIVE completed enrollment in March 2024, exceeding the target of 90 patients with a total of 113 patients enrolled, due to strong patient demand. Topline data from THRIVE is expected in September 2024, while THRIVE-2 is on track for topline readout by the end of 2024. Viridian plans to file a Biologics License Application (BLA) for VRDN-001 in the second half of 2025.VRDN-003 Program
Viridian is also developing VRDN-003, a subcutaneous version of VRDN-001 with an extended half-life, as a potential best-in-class therapy for TED. In a Phase 1 study, VRDN-003 demonstrated a prolonged half-life of 40 to 50 days, which is four to five times longer than that of VRDN-001. This extended half-life could enable less frequent dosing, potentially improving convenience for patients. Viridian recently completed a positive Type C meeting with the FDA and is on track to initiate its pivotal program for VRDN-003 in mid-2024.FcRn Inhibitor Portfolio
In addition to its TED programs, Viridian is developing a portfolio of engineered anti-FcRn inhibitors, including VRDN-006 and VRDN-008, to address the unmet needs of patients living with autoantibody-mediated autoimmune diseases. FcRn inhibitors represent a significant commercial opportunity, as the first FcRn inhibitor, Vyvgart, has already achieved over $1 billion in annual sales. Viridian plans to file an Investigational New Drug (IND) application for VRDN-006 by the end of 2024 and expects to share data on VRDN-008 in non-human primates in the second half of 2024.